U.S. markets closed
  • S&P 500

    3,655.04
    -38.19 (-1.03%)
     
  • Dow 30

    29,260.81
    -329.60 (-1.11%)
     
  • Nasdaq

    10,802.92
    -65.00 (-0.60%)
     
  • Russell 2000

    1,655.88
    -23.71 (-1.41%)
     
  • Crude Oil

    76.57
    -0.14 (-0.18%)
     
  • Gold

    1,631.60
    -1.80 (-0.11%)
     
  • Silver

    18.36
    -0.11 (-0.62%)
     
  • EUR/USD

    0.9602
    -0.0087 (-0.89%)
     
  • 10-Yr Bond

    3.8780
    +0.1810 (+4.90%)
     
  • GBP/USD

    1.0664
    -0.0192 (-1.77%)
     
  • USD/JPY

    144.6690
    +1.3490 (+0.94%)
     
  • BTC-USD

    19,146.61
    +277.59 (+1.47%)
     
  • CMC Crypto 200

    438.96
    +5.86 (+1.35%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

How Eli Lilly Is Thinning Out the Competition

·4 min read

Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets. Early results suggest that the drug could help the company capture crucial share in these key segments.